

Remarks begin on page 7.

AMENDMENTS TO THE CLAIMS

- K1 11/2/20
18. (Currently amended) An ~~anti-human antigen receptor, the receptor antibody or antibody~~ fragment being low or not immunogenic in humans and recognizing the native human 17-1A antigen, ~~the receptor~~ being further characterized as comprising a human-VH chain and a human VL chain wherein at least said VH chain is derived from ~~essentially-unprimed~~ mature human B-lymphocytes and said VL chain is derived from a naturally occurring human B cell repertoire.
19. (Currently amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ according to claim 18, which is an antibody ~~or a fragment~~ thereof.
20. (Canceled) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor recognizing a human tumor antigen.
21. (Canceled) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor recognizing the native human 17-1A antigen.
22. (Currently amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ according to any one of claims 18, 19, 65, 66 or 67, wherein said VH comprises at least one CDR ~~of the amino acid sequence corresponding to encoded by a portion of~~ nucleotides 1 to 381 of Seq. ID NO: 143 and said VL chain comprises at least one CDR ~~of the amino acid sequence corresponding to encoded by a portion of~~ nucleotides 1 to 321 of Seq. ID No: 141.
28. (Currently amended) An ~~anti-human antigen receptor, said receptor antibody or antibody~~ fragment being characterized in that it comprises a human VH chain and a human VL chain ~~that have been functionally rearranged~~, said receptor recognizing the native human 17-1A antigen.
- 11/2/20

- K1
and.
29. (Currently amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ of claim 28, said ~~anti-human antigen receptor antibody or antibody fragment~~ being low or not immunogenic in humans.
31. (Currently amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ of claim 28, recognizing an epitope of the extracellular domain of the 17-1A antigen.
32. (Currently amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ of claim 28, wherein the VH chain comprises the amino acid sequence encoded by at least one of SEQ ID NOS: 143 and/or 145 and/or the VL chain comprises the amino acid sequence encoded by at least one of SEQ ID NOS:141 and/or 147.
34. (Canceled) The anti-human antigen receptor according to claim 18, 65, 66 or 67, said anti-human antigen receptor comprising a VH chain or at least one CDR.
35. (Canceled) The anti-human antigen receptor according to claim 34 wherein said CDR is CDR3.
36. (Canceled) The anti-human antigen receptor according to claim 18, 65, 66 or 67, said receptor comprising a VL chain or at least one CDR.
37. (Canceled) The anti-human antigen receptor according to claim 36 wherein said CDR is CDR3.
38. (Amended) A pharmaceutical composition comprising an ~~anti-human antigen receptor antibody or antibody fragment~~ according to claim 18, 65, 66 or 67, ~~comprising a VH chain and a VL chain and~~ a pharmaceutically acceptable carrier.
39. (Amended) A pharmaceutical composition comprising an ~~anti-human antigen receptor antibody fragment~~ according to claim 19, ~~comprising a VH chain and a VL chain and~~ a pharmaceutically acceptable carrier.
40. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 20, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier.

41. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 21, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier.
42. (Amended) A pharmaceutical composition comprising an ~~anti-human antigen receptor~~ antibody or antibody fragment according to claim 22, ~~comprising a VH chain and a VL chain~~ and a pharmaceutically acceptable carrier.
43. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, 65, 66 or 67, comprising at least one CDR and a pharmaceutically acceptable carrier.
44. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 19 comprising at least one CDR and a pharmaceutically acceptable carrier.
45. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 20 comprising at least one CDR and a pharmaceutically acceptable carrier.
46. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 21 comprising at least one CDR and a pharmaceutically acceptable carrier.
47. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 22 comprising at least one CDR and a pharmaceutically acceptable carrier.
48. (Canceled) A pharmaceutical composition comprising a receptor according to claim 43 wherein said CDR is CDR3.
49. (Canceled) A pharmaceutical composition comprising a receptor according to claim 44 wherein said CDR is CDR3.

50. (Canceled) A pharmaceutical composition according to claim 45 wherein said CDR is CDR3.

51. (Canceled) A pharmaceutical composition according to claim 46 wherein said CDR is CDR3.

52. (Canceled) A pharmaceutical composition according to claim 47 wherein said CDR is CDR3.

K1
Cont.
53. (Amended) A pharmaceutical composition comprising an anti-human antigen receptor antibody or antibody fragment according to claim 28, ~~comprising a VH chain and a VL chain~~ and a pharmaceutically acceptable carrier.

54. (Amended) A pharmaceutical composition comprising an anti-human antigen receptor antibody or antibody fragment according to claim 29, ~~comprising a VH chain and a VL chain~~ and a pharmaceutically acceptable carrier.

55. (Amended) A pharmaceutical composition comprising an anti-human antigen receptor antibody or antibody fragment according to claim 31, ~~comprising a VH chain and a VL chain~~ and a pharmaceutically acceptable carrier.

56. (Amended) A pharmaceutical composition comprising an anti-human antigen receptor antibody or antibody fragment according to claim 32, ~~comprising a VH chain and a VL chain~~ and a pharmaceutically acceptable carrier.

57. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 28 comprising at least one CDR and a pharmaceutically acceptable carrier.

58. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 29 comprising at least one CDR and a pharmaceutically acceptable carrier.

59. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 31 comprising at least one CDR and a pharmaceutically acceptable carrier.

60. (Canceled) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 32 comprising at least one CDR and a pharmaceutically acceptable carrier.

61. (Canceled) A pharmaceutical composition comprising a receptor according to claim 57 wherein said CDR is CDR3.

62. (Canceled) A pharmaceutical composition comprising a receptor according to claim 58 wherein said CDR is CDR3.

63. (Canceled) A pharmaceutical composition comprising a receptor according to claim 59 wherein said CDR is CDR3.

64. (Canceled) A pharmaceutical composition comprising a receptor according to claim 60 wherein said CDR is CDR3.

65. (Amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ according to claim 18, further comprising, fused to said human VH and VL chains, (a) the same or other VH or VL chains, (b) immunoglobulin constant regions of heavy (CH) or light chains (CL) or parts thereof, or (c) non-immunoglobulin chains, respectively.

66. (Amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ according to claim 65, wherein said constant region chains are ~~derived~~ from human IgG1 or IgG3.

67. (Amended) The ~~anti-human antigen receptor antibody or antibody fragment~~ according to claim 18, further comprising linked to said human VH and VL chains a non-proteinous pharmaceutical and/or other biologically active molecule.